Neuroblastoma Research Studies

< Back to Pediatric Cancer Research Studies Page

Neuroblastoma New Diagnosis

ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

PURPOSE: This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in ...More

ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

  • Ages: 365 days to 30 Years

BRIEF SUMMARY: This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor c ...More

Contact Us

Contact us.

To learn more about available neuroblastoma clinical trials, contact us at cancer@cchmc.org or 513-636-2799.